1. Introduction {#s0005}
===============

Overhydration and hypertension are the most common complications in end-stage renal disease (ESRD) patients and are linked to increased mortality [@bib1], [@bib2]. Fluid status is regarded to be the most important factor predisposing dialysis patients to hypertension or hypotension [@bib3]. Many studies have shown that healthy blood pressure levels can be achieved in a large majority of patients, without using anti-hypertensive medication, by avoiding excess extracellular water through accurate fluid status assessment [@bib4], [@bib5].

Clinical evaluation of fluid overload can be difficult in maintenance hemodialysis (MHD) patients and is prone to underestimation or overestimation [@bib6], [@bib7]. Various objective methods have been recommended for defining fluid overload, such as measuring the inferior vena cava diameter, evaluation of N-terminal pro brain natriuretic peptide, lung ultrasonography, and use of a body composition monitor based on bioimpedance spectroscopy (BCM-BIS) [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]. The BCM^®^ (Fresenius Medical Care, Bad Homburg, Germany) is perhaps the best validated device in defining fluid status, with good overall agreement with the gold-standard isotope dilution techniques [@bib14], [@bib15].

Some randomized controlled studies and observational studies have shown that BCM-BIS can help to establish an optimal post-dialysis target weight (PDTW) and obtain better clinical outcomes [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]. However, the best reference range for OH has still not been agreed universally. There may be differences in OH levels among ethnic groups, and OH levels may be affected by the time of measurement (pre- or post-dialysis) and diet (especially sodium intake) [@bib22].

The aim of this study was to establish the optimal target values for post-dialysis overhydration (OH~post~) in anuric MHD normotensive patients, and to provide a management procedure for the adjustment of PDTW, to evaluate whether this approach could improve blood pressure.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

This observational study was performed at the dialysis unit of the BaoTou Central Hospital, Inner Mongolia, China, between October 2017 and January 2018. All patients who were treated for at least 3 months using regular hemodialysis (HD) were included, after obtaining their written informed consent. The study was approved by the institutional ethics committee of the BaoTou Central Hospital. The participants were clinically stable. The following patients were excluded from the study: 1) those aged \< 18 years; 2) those with mechanical valves, pacemakers, coronary artery stents or implanted metallic devices; 3) those with hypotension and cramping in the last six intra-dialysis sessions; 4) those with daily urine ≥ 200 mL.

2.2. Body composition measurements {#s0020}
----------------------------------

In all patients, the assessment of body composition was carried out weekly using the BCM. The measurements were performed approximately 20 min after the mid- or end-week HD session. Regarding the quality of measurements, a numerical indicator was displayed on the same screen as the Cole-Cole plot during measurements; a quality value close to 100% (usually ≥ 90%) and a smooth dome shape for the Cole-Cole plot indicated a successful measurement. BCM measurements were performed at baseline for all subjects.

The parameters obtained using the BCM were over-hydration (OH), total body water, intracellular water (ICW), extracellular water (ECW), ECW to ICW ratio (E/I), fat tissue index (FTI), and lean tissue index (LTI).

2.3. Clinical information {#s0025}
-------------------------

A patient questionnaire documenting sociodemographic status, personal and family health history, dialysis prescription, and medication for hypertension was completed by each patient, with the aid of doctors or nurses. Blood samples for standard laboratory parameters were obtained before the HD session. To improve the reproducibility of the blood pressure measurements, pre-dialytic systolic blood pressure (sBP~pre~) recordings of six previous dialysis sessions were averaged.

2.4. The observational study {#s0030}
----------------------------

OH~post~ was the main parameter used for PDTW adjustment in the current study. The study flow diagram is shown in [Fig. 1](#f0005){ref-type="fig"}. In the observational study, through retrospective analysis of the normotensive group of patients, we obtained a reference value for OH~post~. OH~post~ was combined with LTI to obtain the optimal PDTW adjustment protocol.Fig. 1Study flow diagram.Fig. 1

2.5. The intervention study {#s0035}
---------------------------

In the intervention study, 70 hypertensive MHD patients participated in the study, all of whom were anuric. In accordance with the flow procedure for PDTW adjustment, we adjusted PDTW to the optimal OH~post~ range, with a 0.2--0.5 kg change in PDTW per week. During the period of weight reduction, antihypertensive medication was continually reviewed and progressively reduced where possible.

2.6. Statistical methods {#s0040}
------------------------

Patient characteristics were summarized using standard descriptive statistics. Categorical variables were presented as frequencies and percentages and continuous variables as mean ± standard deviation or as median and interquartile ranges, as appropriate. Baseline differences between normotensive and hypertensive patients were evaluated using an independent samples *t*-test for continuous variables and chi-square tests for categorical variables. Multivariate analysis was performed when differences in variables were significant in the univariate analysis. Comparison between variables was performed through one-way ANOVA in different categorical groups (grouped by OH~post~ data), and *post hoc* analysis was performed using the Bonferroni test. Correlations were also established between the OH~post~ and the variables using the Spearman rho test. Intragroup comparisons were performed using a paired *t*-test.

All statistical tests were performed using the Statistical Package for the Social Sciences 20.0 software. Statistical significance was defined as *p* \< 0.05.

3. Results {#s0045}
==========

3.1. Basic demographic data {#s0050}
---------------------------

There were 75 males (57.692%) and 55 females (42.308%) enrolled in this study. The patient baseline characteristics are shown in [Table 1](#t0005){ref-type="table"}.Table 1Baseline characteristics of the patients.Table 1Parametern = 130Age (y)56.100 ± 12.872Gender \[male/female, n (%)\]75 (57.692%)/55 (42.308%)Etiology, n (%) Chronic glomerulonephritis27 (20.769) Diabetic nephropathy34 (26.154) Hypertensive nephropathy34 (26.154) Polycystic kidney disease5 (3.846) Lupus or vasculitis6 (4.615) Chronic interstitial nephritis5 (3.846) Other3 (2.308) Undetermined16 (12.308)Hemodialysis vintage (mo)41.631 ± 29.372

3.2. Comparison between the groups {#s0055}
----------------------------------

We compared the different clinical parameters and body composition parameters in patient groups with different systolic blood pressures before dialysis (sBP~pre~ \< 140 mmHg and sBP~pre~ ≥ 140 mmHg). The results are summarized in [Table 2](#t0010){ref-type="table"}. Except for lower antihypertensive medication (AHT), lower OH~post~, and lower E/I ratio in the sBP~pre~ \< 140 mmHg group, no clinical and body composition parameters were different between the sBP~pre~ \< 140 mmHg group and the sBP~pre~ ≥ 140 mmHg group.Table 2Patient clinical parameters and body composition differences between groups.Table 2Grouped by systolic blood pressure before dialysis (n = 130)*t or χ*^*2*^*pBeta Expp*sBP~pre~ \< 140 mmHg (n = 60)sBP~pre~ ≥ 140 mmHg (n = 70)**Age (y)**55.233 ± 13.64256.743 ± 12.277− 0.6640.508**Sex (f/m)**27/3328/420.3310.565**Vintage (mo)**40.450 ± 31.27242.257 ± 27.974− 0.3480.729**Diabetes mellitus (%)**17 (28.333%)17 (24.286%)0.2740.601**Ultrafiltration volume (mL)**2354.167 ± 781.9632387.143 ± 820.555− 0.2330.816**AHT**0.783 ± 0.9931.586 ± 1.222− 4.0640.000**Hemoglobin (g/L)**121.867 ± 15.546119.029 ± 15.8991.0250.307**Creatinine (mmol/L)**918.983 ± 263.320878.300 ± 244.4620.9130.363**Serum albumin (g/L)**40.885 ± 3.12841.260 ± 3.287− 0.6630.508**Na**^**+**^**(mmol/L)**139.450 ± 3.321138.571 ± 2.9321.6020.112**Body mass index**23.303 ± 3.66822.743 ± 4.6490.7540.452**OH**~**post**~**(L)**− 0.958 ± 1.1600.267 ± 1.672− 4.7760.0002.2930.000**Total body water (L)**27.812 ± 5.67228.120 ± 6.315− 0.2910.772**Extracellular water (L)**12.253 ± 2.19513.024 ± 2.952− 1.6660.0981.0690.458**Intracellular water (L)**15.558 ± 3.77914.674 ± 4.4541.2090.229**E/I**0.806 ± 0.1180.876 ± 0.126− 3.2380.0020.2780.596**Lean tissue index (kg/m**^**2**^**)**11.392 ± 2.70211.286 ± 2.6940.2230.824**Fat tissue index (kg/m**^**2**^**)**12.180 ± 4.38511.534 ± 3.7380.9060.366[^1]

Multivariate logistic regression analysis based on OH~post~, E/I ratio, and ECW parameters showed that only OH~post~ was significantly associated with sBP~pre~ ≥ 140 mmHg (odds ratio (*OR*) = 2.293, *p* = 0.000).

3.3. Relationships between OH~post~ and clinical presentation in the sBP~pre~ \< 140 mmHg group {#s0060}
-----------------------------------------------------------------------------------------------

The OH~post~ data in the sBP~pre~ \< 140 mmHg group were normally distributed with a mean of − 0.958 ± 1.160 L. The normal distribution of the OH~post~ in this cohort is summarized in [Table 3](#t0015){ref-type="table"}. To detect possible relationships between patient OH~post~ and clinical presentation, we compared the different clinical parameters in sBP~pre~ \< 140 mmHg group patients in different OH~post~ ranges. In accordance with the OH~post~ data quartiles, the patients were grouped into OH~post~ \< −1.8 L, OH~post~ − 1.8 to − 0.25 L and OH~post~ \> −0.25 L ([Table 4](#t0020){ref-type="table"}). Patients in the OH~post~ \< −1.8 L group were mainly male and younger, had higher post-dialysis diastolic blood pressure (dBP~post~), higher ultrafiltration volume (UFV), increased levels of nutrition markers (serum albumin and creatinine), a higher body mass index (BMI), and higher LTI. We did not find a significant association between OH~post~ and dialysis vintage, diabetes mellitus, hemoglobin, AHT, or FTI ([Table 4](#t0020){ref-type="table"}).Table 3Summary statistics of OH~post~ and LTI in 60 normal systolic blood pressure patients.Table 3VariableMean ± SDRange5th pctl10th pctl25th pctl50th pctl75th pctl90th pctl95th pctlOH~post~ (L)− 0.958 ± 1.160− 3.100 − 2.900− 2.595− 2.490− 1.800− 0.950− 0.2500.4901.085LTI **(**kg/m^2^)11.392 ± 2.7025.900 − 17.20016.98015.53013.00011.1009.7257.9006.835[^2]Table 4The relationship between clinical parameters and hydration status in the sBPpre \< 140 mmHg group.Table 4**Grouped by OH**~**post**~**(n = 60)\< −1.8 L− 1.8 to − 0.25 L\> −0.25 LAge (yr)**41.214 ± 9.023 \* \#59.065 ± 10.93060.400 ± 13.968**Sex (m/f)**12/2^⍰^14/17^⍰^7/8^⍰^**Vintage (mo)**30.500 ± 18.24547.000 ± 20.98745.600 ± 46.394**Diabetes mellitus (%)**1/1410/316/15**sBP**~**post**~**(mmHg)**130.500 ± 7.133128.387 ± 9.711128.333 ± 9.217**dBP**~**post**~**(mmHg)**81.214 ± 5.899^&^74.581 ± 7.93270.400 ± 12.894**Antihypertensive medication**1.071 ± 0.9970.710 ± 1.0710.667 ± 0.817**Ultrafiltration volume (L)**2864.286 ± 874.077^§^2295.161 ± 618.9182000.000 ± 802.674**serum albumin (g/L)**42.686 ± 3.321^\$^40.765 ± 2.36839.453 ± 3.672**Creatinine (mmol/L)**1186.500 ± 177.341^£¥^883.548 ± 230.276742.533 ± 204.133**Hemoglobin (g/L)**117.929 ± 14.248124.032 ± 13.870121.067 ± 19.779**Body mass index (kg/m2)**24.457 ± 3.499^վ^23.884 ± 3.471^ֆ^21.027 ± 3.449**Lean tissue index(kg/m**^**2**^**)**13.914 ± 2.089^∮∏^11.084 ± 2.3449.673 ± 2.281**Fat tissue index (kg/m**^**2**^**)**11.400 ± 4.73113.116 ± 4.36710.973 ± 3.907[^3][^4][^5][^6][^7][^8][^9][^10][^11]

Multivariate regression analysis was performed to identify the independent predictors of OH~post~ in the sBP~pre~ \< 140 mmHg group. Multiple stepwise regression analysis was performed using OH~post~ as the dependent variable, and clinical parameters including age, sex, BMI, dBP, UFV, creatinine, serum albumin, and LTI as independent variables. Only LTI was an independent predictor of OH~post~ \[R^2^ = 0.208, β = −0.196, 95% CI (−0.296, −0.095), *p* \< 0.001\]. A correlation was observed between OH~post~ and LTI (γ = −0.456, *p* \< 0.001).

3.4. Flow procedure for PDTW adjustment protocol {#s0065}
------------------------------------------------

In accordance with the above results, OH~post~ and LTI were the main parameters used for post-dialysis target weight (PDTW) adjustment. The reference value for OH~post~ was determined by excluding values lower than the 10th percentile and higher than the 90th percentile for data collected from normotensive patients, yielding − 2.5 L and 0.5 L, respectively. LTI data in the sBP~pre~ \< 140 mmHg group were normally distributed with a mean of 11.392 ± 2.702 kg/m^2^. The normal distribution of the LTI in this cohort is summarized in [Table 3](#t0015){ref-type="table"}. We chose the 50th percentile (LTI = 11.1 kg/m^2^ and OH~post~ = −1.0 L) as the cut-off value for the PDTW adjustment protocol. A flow diagram showing the PDTW adjustment procedure is provided in [Fig. 2](#f0010){ref-type="fig"}. When patients have symptomatic hypotension and severe cramps, the adjustment must be stopped whether or not the blood pressure is normal.Fig. 2Flow diagram showing the PDTW adjustment procedure with BCM results in hypertensive patients. The 50th percentile values for OH~post~ and LTI were − 1.0 L and 11.1 kg/m^2^, respectively.Fig. 2

3.5. Interventional study in sBP~pre~ ≥ 140 mmHg patients {#s0070}
---------------------------------------------------------

The adjustment flow procedure of the interventional study is depicted in [Fig. 2](#f0010){ref-type="fig"}. Of the 70 hypertensive patients who underwent PDTW adjustments, four were excluded from further analysis because of a lack of follow-up (n = 3) or death (n = 1), leaving a total of 66 patients in the interventional study cohort. Of these, the systolic blood pressure of 38 patients (57%) was less than 140 mmHg after PDTW adjustment ([Fig. 3](#f0015){ref-type="fig"}). The changes in OH~post~ from the initial to last adjustment were significant (*t* = 5.431, *p* \< 0.001), with a substantial decrease in the sBP~pre~ (*t* = 11.208, *p* \< 0.001). Consequently, the systolic blood pressure of 28 patients (43%) did not reach the normotensive level after PDTW adjustment. The changes in OH~post~ and sBP~pre~ from the initial to last adjustment failed to reach statistical significance (*t* = 1.820, *p* = 0.080; *t* = 1.162, *p* = 0.255). Twelve patients had intradialytic symptoms in the last study week (eight patients suffered cramps, two suffered hypotensive episodes, one suffered cold sweating, and one suffered hoarseness). Of these, five patients (including two hypotensive patients and three patients who experienced cramps) were in the blood pressure target achievement group, and seven were in the blood pressure target non-achievement group.Fig. 3Changes in OH~post~ (a) and sBP~pre~ (b) in blood pressure target achievement patients. Each box summarizes the results before and after PDTW adjustments. The target range for OH~post~ after dialysis treatment (0.5 to −2.5 L) is indicated. The boundaries of the boxes are the 25th and the 75th percentiles.Fig. 3

4. Discussion {#s0075}
=============

Among the factors causing hypertension in MHD patients, overhydration is thought to be the most important [@bib23], [@bib24], [@bib25]. Dry weight is more important in anuric MHD patients. Persistent hypervolemia causes hypertension and congestive heart failure, and leads to higher mortality. At present, there is no objective gold standard method to estimate target dry weight, and clinical assessment is unreliable. Recently, a meta-analysis reported that bioimpedance analysis-based interventions for the correction of overhydration improved systolic blood pressure control in end-stage kidney disease [@bib26]. Moissl et al. reported that every 1 L change in fluid overload was accompanied by a 9.9 mmHg/L change in pre-dialysis systolic blood pressure [@bib21]. In the current study, we found that only OH~post~ was significantly associated with sBP~pre~ ≥ 140 mmHg (*OR* = 2.293, *p* = 0.000). OH~post~ was one of most important and potentially adjustable causes of hypertension in MHD patients.

Although detailed BCM-based dry weight adjustment protocols have been previously published, there is still no uniform reference range for OH [@bib16], [@bib18], [@bib21], [@bib27]. There are multiple reasons for the discrepancies in the target range, including different BCM measuring times, different ethnic groups and subjects, ages, sodium intake, variations in daily urine volume, and different body compositions. To minimize the effects of these factors, we selected subjects with daily urine \< 200 mL and without hypotension or cramping during the last six intra-dialysis sessions. Chen et al. provided a simple and applicable algorithm for PDTW adjustment with BCM-BIS. The only shortcoming was that OH~post~ was the only parameter in the algorithm, and the range of reference values was derived from MHD patients generally [@bib18]. Our clinical experience indicated that MHD patients with different nutritional statuses had different tolerances to ultrafiltration, suggesting that the optimal OH~post~ range for particular MHD patients may be associated with nutritional parameters. This was confirmed in the current study, in which patients in the OH~post~ \< −1.8 L group were mainly male and younger, and had higher dBP~post~, UFV, levels of nutrition markers (serum albumin and creatinine), BMI, and LTI. In the multivariate regression analysis, only LTI was an independent predictor of OH~post~ \[R^2^ = 0.208, β = −0.196, 95% CI (−0.296, −0.095), *p* \< 0.001\]. Therefore, we chose OH~post~ and LTI as the main parameters for PDTW adjustment. In the current study, the reference value of the OH~post~ was determined by excluding values lower than the 10th percentile and higher than the 90th percentile for data collected from normotensive patients, yielding − 2.5 L and 0.5 L, respectively. We also chose the 50th percentile (LTI = 11.1 kg/m^2^ and OH~post~ = −1.0 L) as the cut-off value for the PDTW adjustment protocol ([Fig. 2](#f0010){ref-type="fig"}).

The novelty of this study includes its use of OH~post~ combined with LTI to adjust the PDTW. It considers differences in body composition, which makes the management strategy for OH~post~ safer and more patient-specific. Although we used the PDTW adjustment protocol to guide better blood pressure control, we still insisted that if adverse reactions happened during adjustment, we would not force patients to reach the target. Using our PDTW adjustment protocol, up to 57% of hypertensive patients showed a significant change in OH~post~ from the initial to last adjustment (*t* = 5.431, *p* \< 0.001) with a substantial decrease in the sBP~pre~ (*t* = 11.208, *p* \< 0.001) ([Fig. 3](#f0015){ref-type="fig"}). Lowering dry weight in dialysis patients can lead to intradialytic complications [@bib28]. Previous studies have relied on the clinician\'s best judgment and clinical experience of volume assessment, and found that a strict dry-weight control may lead to vascular access problems and an increased number of hospitalizations [@bib29]. In the current study, two of the 38 blood pressure target achievement patients could not be brought into the target range of the OH~post~ because of hypotension or for personal reasons. For patients whose OH~post~ was within the reference range, four patients had intradialytic symptoms in the last study week (three patients with cramps, one patient with hypotensive episodes). However, these complications did not result in hospitalization or other adverse outcomes. Although the systolic blood pressure of 28 patients (43%) did not reach the normotensive level after PDTW adjustment, more than 75% of patients showed a systolic blood pressure of under 160 mmHg. The changes in OH~post~ and sBP~pre~ from the initial to last adjustment failed to reach statistical significance (*t* = 1.820, *p* = 0.080; *t* = 1.162, *p* = 0.255). There are several factors to be considered in this context. First, nine patients were not willing to decrease their PDTW, although the BCM clearly indicated overhydration. Second, the OH~post~ of 19 patients was in the reference range, but their blood pressure was above normotensive level. Some studies have also reported that a small subgroup of dialysis patients demonstrate a state of normohydration but have an elevated mean systolic BP. It was not possible to control hypertension through fluid removal because of hypotension and ischemia [@bib25]. In the current study, we also observed that adverse effects were more common in these patients (five patients suffered cramps, one suffered cold sweating, and one suffered hoarseness). It remains to be demonstrated whether improved control of blood pressure in these patients is possible by following different management strategies.

There were limitations to this study. First, the present study was conducted in one medical center and included a relatively small number of patients. Patients were not randomized into control and intervention groups, and the accuracy of the management strategy for OH~post~ adjustment in hypertension patients requires further study. A second limitation is that the study had a short follow-up period. Charra et al. reported a lag phenomenon in blood pressure control in dialysis patients [@bib30]. Our results showed that OH~post~ reduction was associated with an improvement in blood pressure in 57% of patients, and that it might be possible in the future to increase the percentage if a longer follow-up period was used. Third, there was no examination of sleep apnea, renal artery stenosis, primary aldosteronism or pheochromocytoma in our patient exclusion criteria, which may have an impact on the results.

In conclusion, this is one of the first prospective studies to detect the optimal OH~post~ target in anuric MHD patients. This study provided an effective and applicable management strategy for PDTW that can either normalize blood pressure or make hypertension easier to control in the great majority of anuric MHD patients. It considers differences in body composition (LTI), which makes this management strategy safer and more patient-specific than previous approaches.
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[^1]: sBP~pre~, pre-dialysis systolic blood pressure; AHT, antihypertensive medication;OH~post~, post-dialysis overhydration.

[^2]: OH~post~, post-dialysis overhydration; LTI, lean tissue index.

[^3]: OH~post~, post-dialysis overhydration; sBP~post~, post-dialysis systolic blood pressure; dBP~post~, post-dialysis diastolic blood pressure.

[^4]: \* : \< −1.8 L Vs − 1.8〜− 0.25 L, P \< 0.001; \#, \< −1.8 L Vs \> −0.25 L, P = 0.000.

[^5]: &: \< −1.8 L Vs \> −0.25 L, P = 0.006.

[^6]: ∮: \< −1.8 L Vs − 1.8〜− 0.25 L, P = 0.001; ∏, \< −1.8 L Vs \> −0.25 L, P = 0.000.

[^7]: \$: \< −1.8 L Vs \> −0.25 L, P = 0.014.

[^8]: £ : \< −1.8 L Vs − 1.8〜− 0.25 L, P \< 0.001; ¥, \< −1.8 L Vs \> −0.25 L, P = 0.000.

[^9]: §: \< −1.8 L Vs \> −0.25 L, P = 0.007.

[^10]: Վ: \< −1.8 L Vs \> −0.25 L, P = 0.030; ֆ: − 1.8〜− 0.25 L Vs \> −0.25 L, P = 0.034.

[^11]: ⍰: p = 0.031.
